X0508 4 2024-06-21 true 0001822462 Foghorn Therapeutics Inc. FHTX 0001913484 Cavalie Fanny 500 TECHNOLOGY SQUARE STE #700 CAMBRIDGE MA 02139 false true false false Chief Strategy/Bus Ops Officer false Common Stock 86992.00 D Stock Options (Right to buy) 0.73 2028-03-27 Common Stock 5575.00 5575.00 D Stock Options (Right to buy) 3.72 2029-02-12 Common Stock 10135.00 10135.00 D Stock Options (Right to buy) 8.77 2030-08-17 Common Stock 59459.00 59459.00 D Stock Options (Right to buy) 16.63 2031-01-27 Common Stock 50000.00 50000.00 D Stock Options (Right to buy) 14.87 2032-01-25 Common Stock 125000.00 125000.00 D Stock Options (Right to buy) 8.38 2033-01-25 Common Stock 65000.00 65000.00 D Stock Options (Right to buy) 3.06 2034-01-23 Common Stock 80000.00 80000.00 D The option vested as to 25% of the underlying shares of common stock on March 19, 2019, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 30, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended. /s/ Michael LaCascia, Attorney-in-Fact for Fanny Cavalie 2024-06-24